Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06053814 · ClinicalTrials.gov registry record · Phase 1
NS-050/NCNP-03 in Boys With DMD (Meteor50)
A Phase 1 study of Duchenne Muscular Dystrophy, sponsored by NS Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 18
- Study locations
NCT06053814 is a Phase 1 study of Duchenne Muscular Dystrophy that is actively recruiting participants, run by NS Pharma. The registered enrollment target is 20 participants, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (95% lower). The trial reports 18 study locations across 14 states.
The verdict
NCT06053814, a Phase 1 study of Duchenne Muscular Dystrophy, is actively recruiting participants, sponsored by NS Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NS-050/NCNP-03
Study Locations (18)
Other
- Seoul National University Hospital - Seoul
- Ankara Bilkent City Hospital - Ankara
- Istanbul University - Istanbul
- Yeditepe University Kosuyolu Hospital - Istanbul
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
California
- Children's Hospital Los Angeles - Los Angeles
Colorado
- Children's Hospital Colorado - Aurora
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Kansas
- University of Kansas Medical Center - Kansas City
Alberta
- Alberta Children's Hospital - Calgary
British Columbia
- British Columbia Children's Hospital - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-18 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06053814
The ClinicalTrials.gov registry entry for NCT06053814 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (95% lower). The listed sponsor is NS Pharma, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06053814 reports 18 study locations spanning 14 distinct geographic areas - top geographies include Other, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT06053814 about?
NCT06053814 is a clinical study titled "NS-050/NCNP-03 in Boys With DMD (Meteor50)". This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.
What is the current status of trial NCT06053814?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-09-18. Estimated completion is 2027-05.
What conditions does trial NCT06053814 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.
What interventions are being tested in trial NCT06053814?
The interventions under investigation include: Placebo (DRUG), NS-050/NCNP-03 (DRUG).
Who is sponsoring clinical trial NCT06053814?
This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06053814 being conducted?
This trial has 18 study locations across California, Colorado, Illinois, Kansas, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
RECRUITING · Phase 1
-
Trial of Cell Based Therapy for DMD
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 1
-
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
ACTIVE NOT RECRUITING · Phase 1
-
Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.